Posts

Showing posts with the label dysregulated aldosteronism

provoked thromboembolism: longterm anticoag

  A recent article found that adults with a provoked venous thromboembolism (VTE) and enduring risk factors are still at risk for a recurrent VTE event and do benefit from long-term anticoagulation, in the company-funded HI-PRO study  (see  dvt provoked prolonged anticoag NEJM2025  in dropbox, or DOI: 10.1056/NEJMoa2509426)   Details : -- 600 adults who had had an objectively-confirmed symptomatic venous thromboembolism (VTE) after a transient provoking risk factor (eg, autoimmune disorders, chronic lung disease, obesity) and had completed the at least 3-month course of anticoagulation were randomized to apixaban 2.5mg twice a day vs placebo for 12 months, in this single-center, double-blind trial done at the Brigham and Women's Hospital in Boston from November 2020 through November 2023 --mean age 59.5, 57% female, 81% white/12% Black/ 9% Latino -- BMI 31, current smokers 5%  -- coexisting conditions: VTE prior to this trial in 21%; diabetes...

new hypertension guidelines

  Two sets of new hypertension guidelines were developed recently, one by the European Society of Cardiology (ESC) in 2024; the other by the American College of Cardiology/American Heart Association in 2025 (the ESC guidelines predated the 2025 ACC/AHA guidelines). In the following, I will compare the 2024 ESC guidelines mostly to the 2017 ACC/AHA guidelines (see https://gmodestmedblogs.blogspot.com/2017/11/new-aha-hypertension-guidelines.html ), since the updated 2025 ACC/AHA guidelines added very few new recommendations.   ACC/AHA guidelines: see:  htn 2025 AHA guidelines JACC2025  in dropbox, or doi.org/10.1016/j.jacc2025.05.007 ESC guidelines: htn 2024 european guidelines HTN2025  in dropbox, or doi/suppl/10.1161/HYPERTENSIONAHA.124.24173.   -- here is the list of all of their summary points of "what is new" in the 2025 AHA/ACC guidelines' new and revised recommendations beyond the 2017 AHA/ACC guidelines (these new guidelines are quite l...

Hyperaldosteronism 2025 guidelines

  Hyperaldosteronism 2025 guidelines  Modest, Geoffrey (HMFP - Medicine) ​ Modest, Geoffrey (HMFP - Medicine) ​   a recent clinical practice guideline for primary aldosteronism was just published by the Endocrine Society: see  aldosteronism practice guideline JClinEndoMetab2025  in dropbox, or doi.org/10.1210/clinem/dgaf284). this is a 43 page document, so i will present their major recommendations applicable to the primary care outpatient setting, with my commentary (thanks to Ian Huntington for bringing this to my attention) Recommendations -- All patients with hypertension should be screened for primary aldosteronism (PA) by measuring aldosterone and renin levels, and determining the aldosterone-to-renin ratio     -- very little direct data supporting this (only one large retrospective VA study), finding that very few people were screened for PA (1.6%)         -- international studies in Canada, Australia and several E...